Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Pascual

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer PatientsJavier Pascual, Miguel Gil-Gil, Paula Proszek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast CancerÁngel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, et al.
Journal of Neuroengineering and Rehabilitation|July 5, 2013
MUNDUS project: MUltimodal neuroprosthesis for daily upper limb supportAlessandra Pedrocchi, Simona Ferrante, Emilia Ambrosini, et al.
NPJ Breast Cancer|May 20, 2026
Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancerJesús Velasco-Suelto, María Elena Quirós-Ortega, Javier Pascual, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2019
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Paula Proszek, Javier Pascual, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
NPJ Breast Cancer|May 15, 2024
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patientsAlfonso Alba-Bernal, Ana Godoy-Ortiz, María Emilia Domínguez-Recio, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Frontiers in Oncology|March 12, 2026
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern SpainAlejandro Falcón-González, Elisenda Llabrés-Valenti, Fernando Henao-Carrasco, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer PatientsJavier Pascual, Miguel Gil-Gil, Paula Proszek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast CancerÁngel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, et al.
Journal of Neuroengineering and Rehabilitation|July 5, 2013
MUNDUS project: MUltimodal neuroprosthesis for daily upper limb supportAlessandra Pedrocchi, Simona Ferrante, Emilia Ambrosini, et al.
NPJ Breast Cancer|May 20, 2026
Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancerJesús Velasco-Suelto, María Elena Quirós-Ortega, Javier Pascual, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2019
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Paula Proszek, Javier Pascual, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
NPJ Breast Cancer|May 15, 2024
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patientsAlfonso Alba-Bernal, Ana Godoy-Ortiz, María Emilia Domínguez-Recio, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Frontiers in Oncology|March 12, 2026
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern SpainAlejandro Falcón-González, Elisenda Llabrés-Valenti, Fernando Henao-Carrasco, et al.
Pageof 12